Trial Profile

Phase IIIb, observer-blind study to compare immunogenicity of GSK Biologicals' HPV [human papillomavirus]-16/18 L1/AS04 vaccine [Cervarix] versus Gardasil [Quadrivalent Human Papillomavirus (HPV-6,11,16,18,L1 VLP) Recombinant Vaccine Merck & Co., Inc.].

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

07 Jul 2010 Results presented at the 26th International Papillomavirus Congress according to a media release from GlaxoSmithKline.
29 Oct 2009 18-month results were presented at ADSA 2009.
04 Oct 2009 7-month results were presented at FIGO 2009.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com